Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Technical advance

Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer

Authors: Mark Jesus M Magbanua, Eduardo V Sosa, Janet H Scott, Jeff Simko, Colin Collins, Dan Pinkel, Charles J Ryan, John W Park

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

The number of circulating tumor cells (CTCs) in metastatic prostate cancer patients provides prognostic and predictive information. However, it is the molecular characterization of CTCs that offers insight into the biology of these tumor cells in the context of personalized treatment.

Methods

We developed a novel approach to isolate CTCs away from hematopoietic cells with high purity, enabling genomic analysis of these cells. The isolation protocol involves immunomagnetic enrichment followed by fluorescence activated cell sorting (IE/FACS). To evaluate the feasibility of isolation of CTCs by IE/FACS and downstream genomic profiling, we conducted a pilot study in patients with metastatic castration resistant prostate cancer (CRPC). Twenty (20) sequential CRPC patients were assayed using CellSearch™. Twelve (12) patients positive for CTCs were subjected to immunomagnetic enrichment and fluorescence activated cell sorting (IE/FACS) to isolate CTCs. Genomic DNA of CTCs was subjected to whole genome amplification (WGA) followed by gene copy number analysis via array comparative genomic hybridization (aCGH).

Results

CTCs from nine (9) patients successfully profiled were observed to have multiple copy number aberrations including those previously reported in primary prostate tumors such as gains in 8q and losses in 8p. High-level copy number gains at the androgen receptor (AR) locus were observed in 7 (78%) cases. Comparison of genomic profiles between CTCs and archival primary tumors from the same patients revealed common lineage. However, high-level copy number gains in the AR locus were observed in CTCs, but not in the matched archival primary tumors.

Conclusions

We developed a new approach to isolate prostate CTCs without significant leukocyte admixture, and to subject them to genome-wide copy number analysis. Our assay may be utilized to explore genomic events involved in cancer progression, e.g. development of castration resistance and to monitor therapeutic efficacy of targeted therapies in clinical trials in a relatively non-invasive manner.
Appendix
Available only for authorised users
Literature
1.
Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer. 2004, 4 (6): 448-456. 10.1038/nrc1370.CrossRefPubMed
2.
Cristofanilli M, Mendelsohn J: Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?. Proc Natl Acad Sci USA. 2006, 103 (46): 17073-17074. 10.1073/pnas.0608651103.CrossRefPubMedPubMedCentral
3.
Pantel K, Brakenhoff RH, Brandt B: Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008, 8 (5): 329-340. 10.1038/nrc2375.CrossRefPubMed
4.
Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, et al: Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005, 23 (7): 1420-1430. 10.1200/JCO.2005.08.140.CrossRefPubMed
5.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004, 351 (8): 781-791. 10.1056/NEJMoa040766.CrossRefPubMed
6.
de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D: Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008, 14 (19): 6302-6309. 10.1158/1078-0432.CCR-08-0872.CrossRefPubMed
7.
Waldman FM, DeVries S, Chew KL, Moore DH, Kerlikowske K, Ljung BM: Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J Natl Cancer Inst. 2000, 92 (4): 313-320. 10.1093/jnci/92.4.313.CrossRefPubMed
8.
Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, et al: Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007, 13 (23): 7053-7058. 10.1158/1078-0432.CCR-07-1506.CrossRefPubMed
9.
Paez JG, Lin M, Beroukhim R, Lee JC, Zhao X, Richter DJ, Gabriel S, Herman P, Sasaki H, Altshuler D, et al: Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res. 2004, 32 (9): e71-10.1093/nar/gnh069.CrossRefPubMedPubMedCentral
10.
Devries S, Nyante S, Korkola J, Segraves R, Nakao K, Moore D, Bae H, Wilhelm M, Hwang S, Waldman F: Array-based comparative genomic hybridization from formalin-fixed, paraffin-embedded breast tumors. J Mol Diagn. 2005, 7 (1): 65-71. 10.1016/S1525-1578(10)60010-4.CrossRefPubMedPubMedCentral
11.
Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmuller G: Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci USA. 1999, 96 (8): 4494-4499. 10.1073/pnas.96.8.4494.CrossRefPubMedPubMedCentral
12.
Fiegler H, Geigl JB, Langer S, Rigler D, Porter K, Unger K, Carter NP, Speicher MR: High resolution array-CGH analysis of single cells. Nucleic Acids Res. 2007, 35 (3): e15-10.1093/nar/gkl1030.CrossRefPubMed
13.
Geigl JB, Speicher MR: Single-cell isolation from cell suspensions and whole genome amplification from single cells to provide templates for CGH analysis. Nat Protoc. 2007, 2 (12): 3173-3184. 10.1038/nprot.2007.476.CrossRefPubMed
14.
Nowak NJ, Miecznikowski J, Moore SR, Gaile D, Bobadilla D, Smith DD, Kernstine K, Forman SJ, Mhawech-Fauceglia P, Reid M, et al: Challenges in array comparative genomic hybridization for the analysis of cancer samples. Genet Med. 2007, 9 (9): 585-595. 10.1097/GIM.0b013e3181461c4a.CrossRefPubMed
15.
Fuhrmann C, Schmidt-Kittler O, Stoecklein NH, Petat-Dutter K, Vay C, Bockler K, Reinhardt R, Ragg T, Klein CA: High-resolution array comparative genomic hybridization of single micrometastatic tumor cells. Nucleic Acids Res. 2008, 36 (7): e39-10.1093/nar/gkn101.CrossRefPubMedPubMedCentral
16.
Snijders AM, Nowak N, Segraves R, Blackwood S, Brown N, Conroy J, Hamilton G, Hindle AK, Huey B, Kimura K, et al: Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet. 2001, 29 (3): 263-264. 10.1038/ng754.CrossRefPubMed
17.
Hamilton G, Brown N, Oseroff V, Huey B, Segraves R, Sudar D, Kumler J, Albertson D, Pinkel D: A large field CCD system for quantitative imaging of microarrays. Nucleic Acids Res. 2006, 34 (8): e58-10.1093/nar/gkl160.CrossRefPubMedPubMedCentral
18.
Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albertson DG, Pinkel D: Fully automatic quantification of microarray image data. Genome Res. 2002, 12 (2): 325-332. 10.1101/gr.210902.CrossRefPubMedPubMedCentral
19.
Olshen AB, Venkatraman ES, Lucito R, Wigler M: Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004, 5 (4): 557-572. 10.1093/biostatistics/kxh008.CrossRefPubMed
20.
Liu W, Xie CC, Zhu Y, Li T, Sun J, Cheng Y, Ewing CM, Dalrymple S, Turner AR, Isaacs JT, et al: Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia. 2008, 10 (8): 897-907.CrossRefPubMedPubMedCentral
21.
Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, et al: High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998, 20 (2): 207-211. 10.1038/2524.CrossRefPubMed
22.
Sun J, Liu W, Adams TS, Sun J, Li X, Turner AR, Chang B, Kim JW, Zheng SL, Isaacs WB, et al: DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate. 2007, 67 (7): 692-700. 10.1002/pros.20543.CrossRefPubMed
23.
Bubendorf L, Kononen J, Koivisto P, Schraml P, Moch H, Gasser TC, Willi N, Mihatsch MJ, Sauter G, Kallioniemi OP: Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 1999, 59 (4): 803-806.PubMed
24.
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995, 9 (4): 401-406. 10.1038/ng0495-401.CrossRefPubMed
25.
Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME: Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010, 56 (9): 1492-1495. 10.1373/clinchem.2010.143297.CrossRefPubMed
26.
Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens JA: Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR. Breast Cancer Res Treat. 2009, 118 (3): 455-468. 10.1007/s10549-008-0290-0.CrossRefPubMed
27.
Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, Pienta KJ, Meropol NJ, Weiner LM, Cohen SJ, Moreno JG, et al: Global gene expression profiling of circulating tumor cells. Cancer Res. 2005, 65 (12): 4993-4997. 10.1158/0008-5472.CAN-04-4330.CrossRefPubMed
28.
Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LW, Uhr JW: Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci USA. 1998, 95 (8): 4589-4594. 10.1073/pnas.95.8.4589.CrossRefPubMedPubMedCentral
29.
Scher HI, Sawyers CL: Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005, 23 (32): 8253-8261. 10.1200/JCO.2005.03.4777.CrossRefPubMed
30.
Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, Chen L, Ewing CM, Eisenberger MA, Carducci MA, et al: Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009, 15 (5): 559-565. 10.1038/nm.1944.CrossRefPubMedPubMedCentral
31.
Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA: Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009, 101 (1): 61-66.CrossRefPubMedPubMedCentral
32.
Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, Levink R, Coumans F, Moreira J, Riisnaes R, et al: Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res. 2009, 69 (7): 2912-2918. 10.1158/0008-5472.CAN-08-3667.CrossRefPubMed
33.
Leversha MA, Han J, Asgari Z, Danila DC, Lin O, Gonzalez-Espinoza R, Anand A, Lilja H, Heller G, Fleisher M, et al: Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res. 2009, 15 (6): 2091-2097. 10.1158/1078-0432.CCR-08-2036.CrossRefPubMedPubMedCentral
34.
Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, et al: Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010, 2 (25): 25ra23-10.1126/scitranslmed.3000403.CrossRefPubMedPubMedCentral
35.
Holcomb IN, Grove DI, Kinnunen M, Friedman CL, Gallaher IS, Morgan TM, Sather CL, Delrow JJ, Nelson PS, Lange PH, et al: Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res. 2008, 68 (14): 5599-5608. 10.1158/0008-5472.CAN-08-0812.CrossRefPubMedPubMedCentral
36.
Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, Bertz S, Harzmann R, Klein CA: Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009, 27 (10): 1549-1556. 10.1200/JCO.2008.17.0563.CrossRefPubMed
37.
Wiedswang G, Borgen E, Schirmer C, Karesen R, Kvalheim G, Nesland JM, Naume B: Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer. 2006, 118 (8): 2013-2019. 10.1002/ijc.21576.CrossRefPubMed
38.
Paris PL, Kobayashi Y, Zhao Q, Zeng W, Sridharan S, Fan T, Adler HL, Yera ER, Zarrabi MH, Zucker S, et al: Functional phenotyping and genotyping of circulating tumor cells from patients with castration resistant prostate cancer. Cancer Lett. 2009, 277 (2): 164-173. 10.1016/j.canlet.2008.12.007.CrossRefPubMed
Metadata
Title
Isolation and genomic analysis of circulating tumor cells from castration resistant metastatic prostate cancer
Authors
Mark Jesus M Magbanua
Eduardo V Sosa
Janet H Scott
Jeff Simko
Colin Collins
Dan Pinkel
Charles J Ryan
John W Park
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-78

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

Copper compound induces autophagy and apoptosis of glioma cells by reactive oxygen species and jnk activation

Research article

Impact of organised cervical screening on cervical cancer incidence and mortality in migrant women in Australia

Research article

Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?

Research article

Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma

Debate

Natural resistance to cancers: a Darwinian hypothesis to explain Peto’s paradox

Research article

A systems biology approach to the global analysis of transcription factors in colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits